Symptom-inhibited Fentanyl Induction

Summary

The goal of this clinical trial is to test a treatment strategy for individuals with opioid use disorder (OUD) who use fentanyl. Participants will receive medically-administered doses of intravenous (IV) fentanyl at intervals until they are comfortable and do not have withdrawal symptoms. They then will be given opioid agonist therapy (OAT) once daily by mouth, which is the current standard treatment for OUD. In this trial, each participant's starting dose of OAT will be tailored to meet their opioid needs, based on the amount of IV fentanyl they received. The main questions this trial aims to answer are: * Is the IV fentanyl protocol feasible and safe for use in a community clinic setting? * Will the protocol result in higher-than-standard starting doses of OAT? Are these doses safe, and will they enable participants to stay on OAT for a longer time?

Timeline

Start

2024-01-29

Primary completion

2025-12-31

Completion

2025-12-31

Publications

• Azar P, Ignaszewski MJ, Harris M, Barazanci Z, Davison R, Wong JSH, Maharaj A, Mathew N, Hall D, Guillemi SA, Foreman J, Barrios R, Montaner JSG. Rapid intravenous symptom-inhibiting fentanyl induction (SIFI) to optimize rotation onto oral opioid agonist therapy among individuals who use unregulated fentanyl: protocol for an open-label, single arm clinical trial. Addict Sci Clin Pract. 2025 Jul 29;20(1):58. doi: 10.1186/s13722-025-00586-7.

Drugs

Indications